Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market.

A scientist in a lab running tests on a variety of biopharmaceuticals.

The research firm is optimistic that the trial will deliver positive results, given prior evidence that has shown beta-amyloid therapies to be effective in earlier stages of the disease. The firm expects the company to generate $4 billion in additional US sales if the treatment is applied to just 2.5% of the estimated 15 million eligible patients.

Eli Lilly has already secured marketing authorization for Kisunla from the Australian Therapeutic Goods Administration. The authorization covers the use of an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer’s. The authorization came on the drug showing slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines. It focuses on areas such as diabetes, oncology, immunology, neuroscience, and obesity, with a mission to develop drugs that improve the lives of people worldwide.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Undervalued Gold Stocks to Buy According To Analysts and 10 Undervalued Tech Stocks Flying Under Wall Street’s Radar.

Disclosure: None.